Working Document, September 2017
PLoS ONE 9(1): e87262. doi:10.1371/journal.pone.0087262
Informe sobre poplaciones clave.
Rapport sur les populations clés.
Conhecimento, atitudes e práticas sobre tuberculose em prisões e no serviço público de saúde
Rev Bras Epidemiol 2013; 16(1): 100-113
BMC Infectious Diseases 2012, 12:352/1471-2334/12/352
Hindawi Publishing Corporation
Tuberculosis Research and Treatment
Volume 2015, Article ID 752709, 7 pages
DHS Working Papers No. 104.
Review
published: 12 August 2016 doi: 10.3389/fpubh.2016.00166
Frontiers in Public Health | www.frontiersin.org 1 August 2016 | Volume 4 | Article 166
Lessons and best practices in empowering pastoralist communities to prevent HIV infection and reduce the impact of AIDS in Ethiopia. Briefing Paper
African Journal of Laboratory Medicine | Vol 7, No 2 | a796 | 06 December 2018
www.jogh.org • doi: 10.7189/jogh.02.020405 ~ December 2012 • Vol. 2 No. 2 • 020405
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
Internationally, there is a growing concern over antimicro-bial resistance (AMR) which is currently estimated to ac-count for more than 700,000 deaths per year worldwide. If no appropriate measures are taken to halt its pro-gress, AMR will cost approximately 10 million lives andabout US$100 trillion... per year by 2050. In contrast tosome other health issues, AMR is a problem that con-cerns every country irrespective of its level of incomeand development as resistant pathogens do not respect borders.Despite the threat presented by AMR, the 2014 WorldHealth Organization (WHO) and the recent O’Neill re-port describe significant gaps in surveillance, standardmethodologies and data sharing. The 2014 WHOreport identified Africa and South East Asia as the regions without established AMR surveillance systems.
Tadesseet al. BMC Infectious Diseases (2017) 17:616 DOI 10.1186/s12879-017-2713-1
more